DUE: June 25, 2025
SBIR Opportunity: Supporting the development of extracellular vesicle technologies for regenerative medical applications.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)